Quickly
Socially
BHARAT BIOTECH
COVID-19 Vaccine Covaxin's Scientific Standards & Commitment is Transparent, Says Bharat Biotech JMD Suchitra Ella
FDA Rejects EUA for Covaxin, 'Suggests' Biologics Licence Application Route For Approval in US
COVID-19 Vaccine Update: Bharat Biotech's COVAXIN Offers Protection Against Beta And Delta Variants of Coronavirus, Claims Study
COVID-19 Vaccination: 25 Crore Doses Of Covishield And 19 Crore Of Covaxin To Be Procured To Achieve Universalization Of Vaccination
After AIIMS Patna, AIIMS Delhi To Start Screening for Clinical Trials of Covaxin on Children From June 7
COVID-19 Vaccine in India: Centre Signs Deal With Biological-E For 2nd Made-In-India Vaccine; Check List Of Other Vaccines That May Roll Out Soon
Covishield, COVAXIN And Sputnik V Now Available for COVID-19 Vaccination in India; Know Price, Gap Between Doses And Other Details About The Coronavirus Vaccines
Bharat Biotech Says Production Batches of COVID-19 Vaccine Covaxin Initiated in March To Be Ready Only in June
COVID-19 Vaccination in India: Centre Creating ‘Artificial Scarcity’ of Coronavirus Vaccines To Benefit Bharat Biotech, Serum Institute', Says AAP Spokesperson Atishi
Covaxin Expected to Receive Regulatory Approval by WHO by July-September 2021, Says Bharat Biotech
COVID-19 Vaccine Update: Bharat Biotech Submits 90% of Documents to WHO for Emergency Use Listing for COVAXIN, Say Sources
Bharat Biotech Likely to Commence Trials of Covaxin, Its COVID-19 Vaccine, on Children from Next Month
COVID-19 Vaccination in India: Bharat Biotech to Ramp Up COVAXIN Production By 200 Million Doses
Covaxin Phase II and III Clinical Trials for 2–18 Age Group To Begin in 10–12 Days, Says Niti Aayog Member VK Paul
COVID-19 Vaccine Update: COVAXIN Phase II/III Clinical Trails in Age Group of 2 to 18 Years to Begin in 10-12 Days
COVAXIN Demonstrates Protection Against New Variants of COVID-19 Found in India & UK, Says Bharat Biotech
